|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:myelodysplastic_syndromes
gptkb:2005
gptkb:FDA
gptkb:Oncology
mantle cell lymphoma
|
|
gptkbp:associated_with
|
gptkb:anemia
gptkb:deep_vein_thrombosis
peripheral neuropathy
skin rash
pulmonary embolism
hyperkalemia
hypersensitivity reactions
increased risk of blood clots
hypophosphatemia
secondary malignancies
hypomagnesemia
|
|
gptkbp:available_in
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:Japan
|
|
gptkbp:available_on
|
gptkb:brand
generic version
|
|
gptkbp:chemical_formula
|
C20 H24 N2 O5 S
|
|
gptkbp:class
|
immunomodulatory drugs
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
cancer therapy
solid tumors
hematological malignancies
|
|
gptkbp:common_dosage_strengths
|
10 mg
5 mg
15 mg
25 mg
2.5 mg
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
history of thrombosis
|
|
gptkbp:developed_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Revlimid
|
|
gptkbp:indication
|
gptkb:cancer_treatment
|
|
gptkbp:ingredients
|
gptkb:lenalidomide
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:dexamethasone
antibiotics
antiviral drugs
other immunosuppressants
antifungal drugs
|
|
gptkbp:invention
|
gptkb:2022
2027
|
|
gptkbp:is_monitored_by
|
liver function tests
renal function
blood counts
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkb:Revlimid
|
|
gptkbp:mechanism_of_action
|
immunomodulatory agent
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:pharmacokinetics
|
modulates immune response
oral bioavailability
inhibits angiogenesis
induces apoptosis
half-life 3-5 hours
|
|
gptkbp:previous_name
|
gptkb:lenalidomide
|
|
gptkbp:produced_by
|
gptkb:Ireland
gptkb:Switzerland
gptkb:United_States
|
|
gptkbp:research
|
clinical trials
combination therapy
pharmacogenomics
biomarker studies
new indications
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
constipation
thrombocytopenia
neutropenia
peripheral edema
|
|
gptkbp:symbolism
|
yes
|
|
gptkbp:trade
|
gptkb:Revlimid
|
|
gptkbp:used_for
|
gptkb:myelodysplastic_syndromes
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Celgene
|
|
gptkbp:bfsLayer
|
4
|